Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Critical Limb Ischemia Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

11 recruiting trials for Critical Limb Ischemia. Eligibility criteria explained in plain English.

TrialFinderData lists 11 Critical Limb Ischemia clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 4 is the largest group at 25% (1 studies); the largest phase groups are Phase 4: 1, Phase 3: 1, Phase 2: 1, Early Phase 1: 1.

Research is led by Oslo University Hospital (1), Centre Hospitalier le Mans (1), Cell Biopeutics Resources Sdn Bhd (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Hyperbaric oxygen therapy (procedure, 1 trial), followed by arterial ultrasound scan, Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Track Critical Limb Ischemia trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03594344

Additional Hyperbaric Oxygen After Lower Extremity Amputation

This study evaluates the effect of additional hyperbaric oxygen therapy after lower extremity amputation. The patients will be randomized after amputation to either a treatment...

Sponsor: Oslo University HospitalEnrolling: 1202 locations
RECRUITINGNCT06296576

Acceleration Time Assessment for Prediction of Critical Limb Ischemia

Critical Limb Ischaemia (CLI), the final stage of arterial disease, is a therapeutic emergency whose prognosis depends largely on the time taken to diagnose it. The growing...

Sponsor: Centre Hospitalier le MansEnrolling: 4313 locations
RECRUITINGPhase 4NCT05854615

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with...

Sponsor: Cell Biopeutics Resources Sdn BhdEnrolling: 31 location
RECRUITINGPhase 3NCT04433572

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major...

Sponsor: Mercator MedSystems, Inc.Enrolling: 2502 locations
RECRUITINGPhase 2NCT06482892

TP03HN106 in Patients With Critical Limb Ischemia

Critical limb ischemia (CLI) is the most severe ischemic stage in peripheral arterial disease (PAD) of the lower limbs, characterized by decreased walking ability, resting pain...

Sponsor: Talengen Institute of Life Sciences, Shenzhen, P.R. China.Enrolling: 151 location
RECRUITINGNCT06066268

miRNAs in Critical Limb Ischemia (miRNACLI)

For the present study, 40 patients affected by critical limb ischemia of different severity will be enrolled: patients affected by critical limb ischemia undergoing subgenual...

Sponsor: IRCCS Policlinico S. DonatoEnrolling: 801 location
RECRUITINGNCT06075940

Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee...

The objective of this prospective, multi-center, clinical investigation is to evaluate the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Up to...

Sponsor: R3 Vascular Inc.Enrolling: 301 location
RECRUITINGNCT06318767

Predictive Value of Systolic Rise Time of the Plantar Arch on the Risk of Major Adverse Limb Events (MALE) and Major...

Peripheral artery disease (PAD), vascular disease of atheromatous origin, is a frequent pathology, with a steady and significant increase in prevalence over the last decades. It...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 1341 location
RECRUITINGNCT05313165

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

Sponsor: LimFlow, Inc.Enrolling: 10020 locations
RECRUITINGEarly Phase 1NCT06204237

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers...

The goal of this Phase 0 clinical trial is to evaluate safety and biodistribution of \[89Zr\]Zr-DFO-APAC in patients with peripheral arterial occlusive disease / critical limb...

Sponsor: Aplagon OyEnrolling: 101 location
RECRUITINGNCT07588295

Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease

Numerous clinical studies have highlighted the role of macrophages in the destabilization of coronary lesions; however, there is limited literature on the relationship between...

Sponsor: Maria Cecilia HospitalEnrolling: 601 location

Frequently Asked Questions

There are currently 11 clinical trials for Critical Limb Ischemia, with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Critical Limb Ischemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Critical Limb Ischemia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.